Similar articles

• Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

  Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Markman M, et al. Gynecol Oncol. 2004 Jun;93(3):699-701. doi: 10.1016/j.ygyno.2004.03.023. Gynecol Oncol. 2004. PMID: 15196867
• A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.

  Caponigro F, Willemse P, Sorio R, Floquet A, van Belle S, Demol J, Tambaro R, Comandini A, Capriati A, Adank S, Wanders J. Caponigro F, et al. Invest New Drugs. 2005 Jan;23(1):85-9. doi: 10.1023/B:DRUG.0000047110.36382.45. Invest New Drugs. 2005. PMID: 15528985 Clinical Trial.
• Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

  Kurzeder C, Sauer G, Deissler H. Kurzeder C, et al. Curr Cancer Drug Targets. 2006 May;6(3):207-27. doi: 10.2174/156800906776842975. Curr Cancer Drug Targets. 2006. PMID: 16712458 Review.
• Resistance to chemotherapy in ovarian carcinoma.

  Lage H, Denkert C. Lage H, et al. Recent Results Cancer Res. 2007;176:51-60. doi: 10.1007/978-3-540-46091-6_6. Recent Results Cancer Res. 2007. PMID: 17607916 Review.
• Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.

  Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, Chi DS. Eisenhauer EL, et al. Am J Obstet Gynecol. 2008 Feb;198(2):213.e1-7. doi: 10.1016/j.ajog.2007.07.003. Am J Obstet Gynecol. 2008. PMID: 18226627